The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone
Abstract Background Denosumab (XgevaTM) is a fully human antibody to RANK-Ligand, an important signal mediator in the pathogenesis of giant cell tumour of bone (GCTB). The use of denosumab in the treatment of GCTB has changed the way in which these tumours are managed over the past years. Case prese...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2021-02-01
|
| Seri Bilgileri: | World Journal of Surgical Oncology |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s12957-021-02143-3 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|